Optinose Announces 1-for-15 Reverse Stock Split

Core Viewpoint - Optinose, Inc. will implement a 1-for-15 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective December 30, 2024 [1][5]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of issued and outstanding shares from approximately 150,829,507 to about 10,055,300 [6]. - The reverse stock split was approved by stockholders on December 23, 2024, and the specific ratio was subsequently approved by the Board [1][6]. - All outstanding options and warrants will be adjusted accordingly, and stockholders will receive cash for any fractional shares based on the closing price on December 30, 2024 [6]. Group 2: Compliance and Future Plans - The reverse stock split aims to help Optinose regain compliance with the $1.00 minimum closing bid price required for continued listing on Nasdaq [5]. - The company will continue to operate under the existing trading symbol "OPTN" on a split-adjusted basis starting December 31, 2024 [1]. Group 3: Additional Information - Broadridge Corporate Issuer Solutions, Inc. will act as the exchange and transfer agent for the reverse stock split, providing instructions to stockholders regarding the exchange process [2]. - Further details about the reverse stock split can be found in Optinose's Definitive Proxy Statement filed with the SEC on December 12, 2024 [7].